Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis The rise and fall of PPRS payments How contributions from the updated PPRS have affected the DH budget for the NHS.
News UK government hires ex-pharma chief to lead pricing talks wi... The Department of Health has appointed a former UK head of Sanofi and Teva to be its chief commerci
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
